PDE5 inhibitor powder formulations and methods relating thereto

US11806314B2 · kind B2 · utility

Assignee

• Respira Therapeutics, Inc. · US

Inventors

• Zhen Xu · Ann Arbor, US
• Hugh Smyth · Austin, US
• Aileen Gibbons · New York, US
• Revati Shreeniwas · Palo Alto, US
• Pravin Soni · Union City, US
• Dan Deaton · Apex, US
• James B. Hannon · Somers, US
• Stephen Lermer · Austin, US
• Robert Curtis · Santa Fe, US
• Martin Donovan · Austin, US

Key dates

• Filing date: Jan 20, 2022
• Grant date: Nov 7, 2023
• Expiry date: Jan 20, 2042

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.